Use of GlcN to increase O-GlcNAcylated protein levels in non-proliferative CLL cells was found to impair TLR7-signaling responses that could be enhanced by an OGT inhibitor but the relevant O-GlcNAcylated proteins were not identified (2). The gene discussed is OGT; the disease is B-cell chronic lymphocytic leukemia.